• Home
  • News
  • Calendar
  • About DF/HCC
  • Membership
  • Visitor Center


    Tumor Imaging Metrics Core

    Under the direction of Annick Van den Abbeele, MD (DFCI) and Gordon Harris, PhD (MGH), the Tumor Imaging Metrics Core (TIMC) provides objective assessment of imaging response to treatments being evaluated through approved cancer clinical trials across the five DF/HCC hospitals (BIDMC, BWH, CHB, DFCI, MGH) using independent tumor measurements of radiological scans (CT, MR and PET).  With convenient locations at BWH, DFCI and MGH, the TIMC produces high-quality data with fast turnaround time

    A first of its kind scaffold vaccine

    For cancer immunologists who have long envisioned a vaccine that would train the immune system to rid itself of cancer, Provenge, the first therapeutic cancer vaccine to receive FDA approval in 2011, is a milestone worth celebrating

    Overcoming cancerís immune suppression

    In 2010 and 2011, the FDA approved two novel cancer immunotherapies, the first therapeutic cancer vaccine called Provenge (sipuleucel-T), and a monoclonal antibody called Yervoy (ipilimumab) for metastatic melanoma

    Request for Applications: Harvard Catalyst Ė Dana-Farber/Harvard Cancer Center Pilot Grant Program
    New research teams funded in pancreatic cancer, glioblastoma

    New research teams funded in pancreatic cancer, glioblastoma

    Dana-Farber/Harvard Cancer Center and the David H

    New awards promote collaboration in womenís cancers research

    Dana-Farber/Harvard Cancer Center has announced its first round of funding through the Menís Collaborative to Cure Womenís Cancers, an unprecedented partnership providing a vehicle for men to support cutting edge research in breast and gynecologic cancers across the DF/HCC community

    Cancer Cell Biology Program: Matchmaker to Interdisciplinary Researchers

    Conquering cancer is too daunting for any one discipline, approach, or individual

Displaying results 43 to 49 out of 206